Indian pharmaceuticals: A long-term story
Inspite of attracive long term growth prospects, Anjan Sen, Director, Deloitte Touche Tohmatsu India, opines that field force…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Improved awareness will lead to better business
Dr Kiran Marthak, Vice Chairman, Medical Sub Committee- IDMA and Head Global Clinical Development, Lambda Therapeutic Research,…
Indian clinical research: A call to self regulate
The Indian clinical research industry is at the crossroads. If 2012 was a year of regulatory discussion and debate, 2013 will see…
Indian pharma: Emerging as global power in R&D
D K Aggarwal, CMD, SMC Investments and Advisors, says that collaboration between the Government and industry holds the key to…
Tech solutions to improve management of drug development programmes
Ted Gastineau, President, ICON Clinical Research explains how the increased use of technology is likely to lead to changes within…
IPR trends in 2013: An alloy of problems and solutions
Milind Sathe, Deputy General Manager-Projects, Unichem Laboratories expresses his views
Transformational change in 2013
Pharma leaders need tp proactively transform themselves in 2013 in order to face the challenges ahead, reasons Dr RB Smarta,…
Modest progress in fiscal and public sector reforms expected
Policy makers should be upbeat in implementing the policy reforms to get the economy back on the track, Abhishek Goenka, Founder…
IPM grows 4.1 per cent, valued at Rs 5939 crore in November 12
Abbott, Sun Pharma cross Rs 300 crore in monthly sales
State drug regulators equally responsible for clinical trial activities: DCGI
In a watchdog role, state regulators now mandated to accompany CDSCO officers on clinical trial site inspections